Oseni and Breastfeeding
Although no studies have been done on using Oseni (alogliptin and pioglitazone) while breastfeeding, the individual components in the drug do pass through breast milk. Because of the potential for serious side effects, the manufacturer recommends that women not use Oseni while nursing. If your healthcare provider recommends this medicine anyhow, watch for any side effects in your child.
Oseni® (alogliptin and pioglitazone) is a prescription medication used in the treatment of diabetes. It contains alogliptin (Nesina®) and pioglitazone (Actos®), two prescription medicines that work in different ways to control blood sugar. At this time, it is not entirely known if Oseni passes through breast milk in women.
The individual components of Oseni, alogliptin and pioglitazone, have been shown to pass through the breast milk of rats. No studies have been done with Oseni. Therefore, it is not entirely known if the drug passes through human breast milk or whether it would harm a nursing child.
Because many medicines pass through breast milk, and because of the potential for serious side effects in a nursing child, the manufacturer of Oseni recommends it not be used in breastfeeding women.
If your healthcare provider recommends Oseni while you are breastfeeding, make sure to watch your child for any possible side effects. Your healthcare provider may also recommend monitoring your nursing child’s blood sugar levels if you take this drug while breastfeeding.
You should discuss breastfeeding and Oseni use with your healthcare provider. Each woman's situation is different, and you and your healthcare provider understand your situation best. After considering what you want and expect, as well as your current health situation, the two of you can make a shared decision that is right for you.